Member Info for EarlyBird-Rns

Blood test breakthrough in search for Alzheimer's cure Test for 10 proteins predicts onset of disease over 12 months in those with mild memory loss with 87% accuracy Share 586 1 inShare 32 Email Sarah Boseley, health editor The Guardian, Tuesday 8 July 2014 Jump to comments (132) Alzheimer's disease brain scan A brain scan of a patient suffering with Alzheimer's disease. The darker areas show a reduction of function and blood flow. Photograph: Alamy A blood test to detect which people with failing memories will go on to develop Alzheimer's disease has been developed by British scientists, who hope it may prove a breakthrough in the hunt for a cure. After a decade's work, an international collaboration led by scientists from King's College London, with the UK company Proteome Sciences, has published a study identifying a set of 10 proteins in the blood. The test can predict the onset of Alzheimer's in the next 12 months in people with memory problems with an accuracy of 87%. It could cost £100-£300 and be available within two years. Alzheimer's and other forms of dementia are distressing and a huge burden on those affected, their families and the NHS. But despite the growing problem as people live longer, there are no good long-term treatments and there is no cure. David Cameron recently announced a drive to discover new drugs for dementia, which he said "stands alongside cancer as one of the greatest enemies of humanity". Many trials have ended in failure. As one potential drug after another has fallen by the wayside, scientists have begun to look for ways to treat people at a much earlier stage, when their brain is not so badly damaged. But to do that, they need a test to predict who is going to develop the disease. A number of research groups have been trying to develop tests. Scientists in the US published details in March of a proposed test for lipids (fatty chemicals) in the blood of people in the general population, who do not have memory problems. Such a screening test would be controversial, however: few healthy people want to know they may be in line for an incurable disease that can be neither prevented nor treated. The new test is aimed at people with the kind of memory loss called mild cognitive impairment, 60% of whom will go on to develop dementia. Those are the people scientists now want to recruit into trials to prevent, or at least delay, the onset of Alzheimer's. "Alzheimer's begins to affect the brain many years before patients are diagnosed with the disease," said Professor Simon Lovestone from King's College. "Many of our drug trials fail because by the time patients are given the drugs, the brain has already been too severely affected. "A simple blood test could help us identify patients at a much earlier stage to take part in new trials and hopefully develop treatments which could prevent the progression of the disease." The researchers inv

Professor Simon Lovestone, senior author of the study from the University of Oxford, who led the work whilst at King's, said: "Alzheimer's begins to affect the brain many years before patients are diagnosed with the disease. Many of our drug trials fail because by the time patients are given the drugs, the brain has already been too severely affected. A simple blood test could help us identify patients at a much earlier stage to take part in new trials and hopefully develop treatments which could prevent the progression of the disease. The next step will be to validate our findings in further sample sets, to see if we can improve accuracy and reduce the risk of misdiagnosis, and to develop a reliable test suitable to be used by doctors." Dr Eric Karran, Director of Research at Alzheimer's Research UK, the UK's leading dementia research charity, said: "As the onset of Alzheimer's is often slow and subtle, a blood test to identify those at high risk of the disease at an early stage would be of real value. Detecting the first signs of Alzheimer's could improve clinical trials for new treatments and help those already concerned about their memory, but we're not currently in a position to use such a test to screen the general population. "With an ageing population, and age the biggest risk factor for Alzheimer's, we are expecting rising numbers of people to be affected over the coming years. It's important to develop new ways to intervene early in the disease to help people maintain their quality of life for as long as possible." Dr Ian Pike, co-author of the paper from Proteome Sciences, said: "By linking the best British academic and commercial research, this landmark study in Alzheimer's disease is a major advance in the development of a simple blood test to identify the disease before clinical symptoms appear. This is the window that will offer the best chance of successful treatment. Equally important, a blood test will be considerably easier and less expensive than using brain imaging or cerebrospinal spinal fluid. "We are in the process of selecting commercial partners to combine the protein biomarkers in a blood test for the global market, a key step forward to deliver effective and early treatment for this crippling disease." Alzheimer's disease is the most common form of dementia. Globally, it is estimated that 135 million people will have dementia by 2050. In 2010, the annual global cost of dementia was estimated at $604 billion. MCI includes problems with day-to-day memory, language and attention, and can be an early sign of dementia, or a symptom of stress or anxiety. Approximately 10% of people diagnosed with MCI develop dementia within a year but apart from regular assessments to measure memory decline, there is currently no accurate way of predicting who will, or won't, develop dementia. - Ends - For further information please contact:

08 July 2014 Proteome Sciences plc Blood test for Alzheimer's moves considerably closer 8(th) July, 2014 - Cobham, UK: Proteome Sciences is pleased to announce publication of a study it has co-authored with King's College London in which a set of 10 proteins in the blood have been identified which can predict the onset of Alzheimer's disease. The study which analysed over 1,000 individuals is the largest of its kind to date and marks a significant step towards developing a blood test for the disease. There are currently no effective long-lasting drug treatments for Alzheimer's, and it is believed that many new clinical trials fail because drugs are given too late in the disease process. A blood test could be used to identify patients in the early stages of memory loss for clinical trials to find drugs to halt the progression of the disease. Secretary of State for Health, Jeremy Hunt, said: "This is welcome research on an issue we've made a national priority. Developing tests and biomarkers will be important steps forward in the global fight against dementia as we search for a cure." The study, published today in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, is the result of an international collaboration led by King's College London and Proteome Sciences plc, funded by Alzheimer's Research UK, the UK Medical Research Council, the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre and Proteome Sciences. The researchers used data from three international studies. Blood samples from a total of 1,148 individuals (476 with Alzheimer's disease; 220 with 'Mild Cognitive Impairment' (MCI) and 452 elderly controls without dementia) were analysed for 26 proteins previously shown to be associated with Alzheimer's disease. A sub-group of 476 individuals across all three groups also had an MRI brain scan. Researchers identified 16 of these 26 proteins to be strongly associated with brain shrinkage in either MCI or Alzheimer's. They then ran a second series of tests to establish which of these proteins could predict the progression from MCI to Alzheimer's. They identified a combination of 10 proteins capable of predicting whether individuals with MCI would develop Alzheimer's disease within a year, with an accuracy of 87 percent. Dr Abdul Hye, lead author of the study from the Institute of Psychiatry at King's College London, said: "Memory problems are very common, but the challenge is identifying who is likely to develop dementia. There are thousands of proteins in the blood, and this study is the culmination of many years' work identifying which ones are clinically relevant. We now have a set of 10 proteins that can predict whether someone with early symptoms of memory loss, or mild cognitive impairment, will develop Alzheimer's disease within a year, with a high level of accuracy." Professor Simon Lovestone, senior author of the study from the Universi

And very nice upwards movement this morning! She has a tiny market cap and few shares on offer... It will take very little volume to get her moving... GLA:)

This has not been looking promising over the last few days and now people jumping ship... What's next..? An Rns stating the share is suspended pending an announcement..? I've seen it happen too many times... GLA

Check out my last post...

1 July, 2014 Jubilant Energy N.V. ("Jubilant", "the Company" or "the Group") Funding Agreement Signed Jubilant is pleased to announce that on June 30, 2014, its two operating subsidiary companies in India entered into funding arrangements with Tower Promoters Private Limited* for unsecured loan facilities aggregating to INR 57,00,00,000 (Rupees Fifty seven Crores) equivalent to approximately USD 9.5 Million (the "Loan"). The Loan has a tenor of one year and an interest rate of 15.5% per annum. These funds will be used for funding the operations of the Group including debt repayments and servicing. The Loan is deemed to be a related party transaction pursuant to AIM Rule 13. The Independent Directors of the Company, having consulted with its nominated adviser, consider that the terms of the Loan are fair and reasonable insofar as its shareholders are concerned. *Tower Promoters Private Limited is directly or indirectly, owned and controlled by Mr S S Bhartia, who is Non Executive Director and Chairman of Jubilant. Mr S S Bhartia, together with Mr H S Bhartia, who is Non Executive Director and Co-Chairman of Jubilant, are the Company's substantial shareholders, holding approximately 85.0% of the voting rights of the Company in aggregate. Enquiries: Jubilant Energy Vipul Agarwal +91 120 7186000 Callum Stewart, Adam Panmure Gordon James +44 20 78862500

Are long and now climbing!

About to climb again...

She's going upwards but still have yet to set a pattern in on the order books...

Buy now... May do a few more...

About to have an upwards tick:)

She's bouncing hard! GLA:)

01 July 2014 Messaging International Plc ('the Company') Unaudited Preliminary Results Messaging International Plc, the AIM traded company and provider of innovative messaging services, announces its unaudited results for the year ended 31 December 2013. The Company expects to be in a position to announce and post to shareholders its audited results for the year ended 31 December 2013 shortly. Accordingly, pursuant to AIM Rule 19, trading in the Company's shares has been suspended as it is not in a position to publish audited accounts for the year ended 31 December 2013 within the required time frame. Overview -- New strategy to be launched in H2/2014, focused on a new product line geared towards a new market: "Secure Mobile Messaging for Enterprises". -- Continued revenue growth - increased by 0.18% to GBP3,775,910 (2012: GBP3,769,263). -- Pre tax loss for the year - GBP92,073 (2012 Profit: GBP290,338) with positive cash flow from operations generated New Strategy for H2/2014: Secure Mobile Messaging for Enterprises. A messaging-suite for enterprises that replicates the ease of use of consumer applications such as WhatsApp, Viber and Facebook while providing all the additional tools that businesses need in order to stay on top of corporate mobile messages which are "MANAGED, SECURE, RELIABLE and IT READY". Enterprise Mobile Messaging in a Nutshell In today's constantly changing workplace, businesses are turning to mobile messaging as an alternative to email. Employers embrace BYOD (Bring Your Own Device) policies, while employees use consumer messaging applications and SMS to communicate with each other. While standard SMS/MMS and IP messages are great for personal communication, they do not provide a way to monitor, secure, archive or manage messages-common business requirements in an organization. Therefore, we've been working hard at TeleMessage to develop an innovative, all-encompassing messaging-suite for enterprises that replicates the ease of use of consumer applications, while providing all the additional tools that businesses need in order to stay on top of corporate mobile messages. In short, we are: "Transforming Business Mobile Messaging" into a service that is "MANAGED, SECURE, RELIABLE and IT READY". We aim to deliver secure, manageable, and reliable messaging solutions that include features such as: end-to-end encryption, message termination, and detailed message delivery status. Our offering will also include our web portal, Outlook plug-in, corporate directory, and a range of APIs that connect to the enterprise IT system. Our vision is to become the mobile messaging solution preferred by enterprises. Our mission is to provide enterprises with messaging solutions that are manageable, secure, reliable, easy to use and offer developer friendly APIs. This new strategy to be launched to the market in H2/2014 will be marketed primarily vi

30 June 2014 SUNKAR RESOURCES PLC ("Sunkar" or the "Company") Annual General Meeting and Operations Update Sunkar (AIM: SKR) announces that, in light of the recommended cash offer made for the Company by Sun Avenue Partners Corp., on 17 June 2014, the board of Sunkar have elected to convene the Company's Annual General Meeting on 19 August 2014, after the date on which such offer either will, or will not, have become unconditional as to acceptances. Accordingly, a separate announcement, including details of the meeting and confirmation of the posting of a Notice of Annual General Meeting and a Form of Proxy for the Annual General Meeting, will be issued in due course. As announced on 2 April 2014, the Company's wholly owned subsidiary Temir-Service LLP ("Temir") agreed an extension to the second earth moving contract with a value of approximately KZT79 million ($434,000). The majority of these works were completed, in terms of volumes, during April 2014 and Temir now expects to complete the final works during the course of July 2014. Temir is also yet to complete approximately 5,000 m(3) of works under the first earth moving contract, as these were delayed due to other critical path workstreams, which had to be completed prior to completion of the embankment, which is the main element of this earth moving contract. Although these works were expected to have been completed by the end of this quarter, Temir now expects to complete these works during the course of July 2014. Enquiries: Sunkar Resources plc Tel: 020 7397 3730 Teck Soon Kong Serikjan Utegen Strand Hanson Limited Tel: 020 7409 3494 Stuart Faulkner Andrew Emmott James Dance Bankside Consultants Tel: 07703 167 065 Simon Rothschild or visit: www.sunkarresources.com This information is provided by RNS The company news service from the London Stock Exchange END MSCLLFVFRLI

30 June 2014 ELECO plc ("ELECO" or "the Company") Trading Statement For The Half Year To 30 June 2014 The Board of ELECO is encouraged by the Group's progress in the first half of 2014. Trading of ELECO's continuing operations in the UK in the period benefited from the upturn in the UK economy, offset to some extent by a more subdued performance in the period from ELECO's continuing operations in Germany and Sweden, reflecting the less buoyant economies in those markets. Overall, however, the trading of our continuing operations was in line with the Board's expectations and turnover and operating profit of our continuing operations are expected to be ahead of that for the equivalent period last year. ELECO's continuing operations now consist solely of businesses engaged in the development and supply of project management, estimation and visualisation software applications serving construction industries principally in the UK, Sweden and Germany, but also in other international markets. The Board of ELECO notes that since 1 January 2014, subsidiary companies of ELECO, which hitherto had been statutory employers of the ELECO Retirement and Benefits Scheme have been placed either into administration or into liquidation. These companies are no longer under control of ELECO and the Board has been advised that the results and balance sheets of these companies should no longer be included in the consolidated results of the ELECO group. The pension scheme liability amounting to GBP6.2m of the ELECO Retirement and Benefits Scheme, net of the associated deferred tax, will therefore be de-recognised from the consolidated balance sheet of the ELECO Group as at 30 June 2014. - ENDS - For further information please contact: ELECO plc

Can I Explain this..? Hmmm.... A few weeks ago I bought into GWIN (I believe@ 2.75p) not for the quality of the company and certainly not for what it has to offer... GWIN is a Chinese based company and as we all know,,, reliability of payments etc... are unreliable while doing business in China.. The reason I took a position was simple... The share price tanked on the day I bought... It's small market cap and few shares on offer... It's was a complete gamble and thankfully I was lucky to end up on the right side of the trade. My point is... Be careful with this share... GLA:)

GLA!

Been holding these for weeks now. @ 2.75p ... Looks like it's finally paying off! GLA!

Out...